- High Dose Rate Brachytherapy
- Low Dose Rate Brachytherapy
Brachytherapy Devices Market size is valued at USD 792.2 million in 2021 and is expected to grow at a CAGR of 7.4% during the forecast period 2022 to 2028. The global market provides a detailed overview of the Brachytherapy Devices market and which can be segmented by type, application, end-user, and region. By type, the Brachytherapy Devices market has been segmented into high dose rate brachytherapy and low dose rate brachytherapy. By type, the high dose rate brachytherapy segment dominated the market and accounted for the largest revenue share in past years. The high dose rate therapy is generally done as an outpatient procedure for the treatment of various types of cancers such as skin, cervical, prostate, head, neck, and breast cancer within a short procedure time, higher efficacy, and protection from radiation exposure. By application, the Brachytherapy Devices market has been segmented into gynecological cancer, prostate cancer, skin cancer, breast cancer, cervical cancer, and others. By application, the breast cancer segment is expected to witness the highest CAGR during the forecast period owing to the increasing usage of brachytherapy in accelerated partial breast irradiation (APBI). Furthermore, the rising incidence of breast cancer is also expected to propel the growth of this segment. Based on the end user, the segment has been segregated into hospitals, diagnostic centers, ambulatory surgical centers, and radiotherapy centers. The radiotherapy centers segment is expected to lead the end-user segments owing to continuous development in cancer treatment devices by numerous radiotherapy centers across developed countries. Key Development: In July 2021, Genesis Care extends U.S. brachytherapy service with 27 Elekta Flexitron treatment devices.
Fastest Growing Market
The rising prevalence of cancer, technological advancements, and a substantial rise in the adoption of brachytherapy are expected to drive the growth of the market during the forecast period.
Based on dosage type, High-Dose Rate (HDR) brachytherapy segment held the largest share in 2020, due to various advantages such as short procedure time, higher efficacy, and protection from radiation exposure.
The increasing prevalence of cancer, technological advancements, and the rise in the adoption of brachytherapy is expected to drive the growth of the market during the forecast period.
The prostate cancer segment dominated the global brachytherapy market and accounted for the largest revenue share in the historic period due to the rising prevalence of prostate cancer across the globe.
North America dominated the global brachytherapy market and held a significant market share, and would expect to expand the global market by making huge investments in healthcare sectors.